NCT03664232View on ClinicalTrials.gov

A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

November 7, 2018

Primary Completion Date

October 17, 2022

Study Completion Date

October 28, 2022

Conditions
Autism Spectrum Disorder
Interventions
DRUG

JNJ-42165279

Participants will receive 25 mg JNJ-42165279 orally twice daily for 12 weeks.

DRUG

Placebo

Participants will receive a matching placebo orally twice daily for 12 weeks.

Trial Locations (9)

10032

New York Presbyterian Hospital, New York

10962

Nathan Kline Institute, Orangeburg

36303

Harmonex Neuroscience Research, Dothan

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

73116

Cutting Edge Research Group, Oklahoma City

78759

BioBehavioral Research of Austin PC, Austin

85006

Southwest Autism Research and Resource Center, Phoenix

92868

NRC Research Institute, Orange

98105

Seattle Children's Hospital, Seattle

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03664232 - A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder | Biotech Hunter | Biotech Hunter